July 31, 2020 -- Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate.
The phase I/II clinical trial will investigate whether a combination of E02401 and an immune checkpoint inhibitor can serve as a treatment for progressive or first recurrent glioblastoma multiforme (GBM), an aggressive form of brain cancer. It will evaluate the candidate's safety, tolerability, immunogenicity, and preliminary efficacy in 32 patients with GBM.
Neuro-oncology researcher Wolfgang Wick, PhD, from Heidelberg University Hospital in Germany, will serve as principal investigator for the open-label trial. Patients will be treated at 10 sites in the U.S. and Europe, with the first results expected in 2022.
Immunotherapy candidate E02401 is derived from Enterome's microbiome-derived peptide antigens known as OncoMimics. The novel candidate combines three OncoMimics found in glioblastoma and other aggressive cancers, the company noted.